# Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout

> **NCT01356498** · PHASE3 · COMPLETED · sponsor: **Savient Pharmaceuticals** · enrollment: 151 (actual)

## Conditions studied

- Gout

## Interventions

- **BIOLOGICAL:** pegloticase

## Key facts

- **NCT ID:** NCT01356498
- **Lead sponsor:** Savient Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 151 (ACTUAL)
- **Last updated:** 2011-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01356498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01356498, "Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01356498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*